Articles From: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials to CNN: Put up or (please) shut up


- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs.
Sign-up for Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials investment picks
Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO , June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus ® ). 1,2,3,4,5,6 Results from these Phase I and Phase III studies were presented at the 74 th American Diabetes Association Scientific Sessions in San Francisco .
Sign-up for Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus® investment picks
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.
Sign-up for CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union investment picks
First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany , June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.
Sign-up for CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European Union investment picks
-- No additional clinical trials requested by the FDA RIDGEFIELD, Conn.
Sign-up for Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA investment picks
TORONTO, July 2, 2014 (GLOBE NEWSWIRE) -- FirstService Corporation (Nasdaq:FSRV) (TSX:FSV) announced today that its subsidiary, Colliers International ("Colliers"), has acquired McKenzie Hall Pty Limited, a specialty retail management and leasing business operating across Australia's east coast.
Sign-up for Colliers International Builds Retail Expertise With Acquisition of Australian-Based McKenzie Hall investment picks
Third product from the BI-Lilly Diabetes alliance to be approved by FDA RIDGEFIELD, Conn.
Sign-up for FDA approves Jardiance® (empagliflozin) tablets for adults with type 2 diabetes investment picks
Company Files Investor Presentation Highlighting Benefits of Proposed Combination with Fyffes CHARLOTTE, N.C., Aug.
Sign-up for Chiquita Mails Letter to Shareholders investment picks
New JARDIANCE Simple Savings program currently offered in doctors' offices and online RIDGEFIELD, Conn.
Sign-up for New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies investment picks
INDIANAPOLIS and RIDGEFIELD, Conn.
Sign-up for FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection) investment picks
2014/7/14
MakerBot and The Home Depot® announce a collaboration to bring MakerBot® Replicator® Desktop 3D Printers to customers on homedepot.com/makerbot and in 12 Home Depot stores in California, Illinois and New York beginning July 14, 2014 .
Sign-up for MakerBot and The Home Depot Bring MakerBot 3D Printers to homedepot.com and Select Stores investment picks
2014/7/10
LAS VEGAS, July 10, 2014 (GLOBE NEWSWIRE) -- Reprinted from July 3, 2014 , this material event warranted another release.
Sign-up for Solid Growth for Hemp, Inc. as Record Revenues and Purchase of Decortication Equipment Increases Value to Its Shareholders investment picks
LAS VEGAS, June 23, 2014 (GLOBE NEWSWIRE) -- Hemp, Inc.'s (OTC:HEMP) wholly owned subsidiary, The Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC), announced today that it has signed a consultant agreement with PPJ Enterprise (OTC:PPJE) , a leader in medical practice information management.
Sign-up for PPJ Enterprise Triples Its Stock Price and Volume After Signing Agreement With Hemp, Inc.'s IHMMCC to Segue Into the Medical Marijuana Sector investment picks
LAS VEGAS, July 3, 2014 (GLOBE NEWSWIRE) -- Hemp, Inc. (OTC:HEMP) has purchased a whole line of automated Temafa decortication equipment designed to separate the fiber from the core of the hemp plant through a process known as decortication.
Sign-up for Bright Future for Hemp, Inc. as Purchase of Decortication Equipment Coupled With Record Revenues Drive Growth and Increased Value to Shareholders investment picks
Ixia (Nasdaq: XXIA) announced a partnership agreement with Empowered Networks , a leading Canadian value-added reseller, to offer service providers, enterprises and network equipment manufacturers more comprehensive and complete solutions to address today's complex network requirements.
Sign-up for Ixia Partners with Empowered Networks to Provide Innovative Visibility and Test Portfolio investment picks
http://media.marketwire.com/attachments/201102/21554_craylogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1126224&ProfileId=051205&sourceType=1 SEATTLE, WA and LEIPZIG, GERMANY --
Sign-up for Cray Joins OpenStack Foundation investment picks
Walgreens (NYSE: WAG) (Nasdaq: WAG) and the United Nations Foundation today announced the launch of the “Get a Shot.
Sign-up for Walgreens and United Nations Foundation Launch “Get a Shot. Give a Shot” Campaign, Kicking Off Second Year of Collaboration to Provide Life-Saving Vaccines for Children in Developing Countries investment picks
2014/8/8
http://media.marketwire.com/attachments/201408/TN-268291_GamesWeek2014.jpg http://media.marketwire.com/attachments/201408/268289_RedboxLogoforPressReleases.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1136459&ProfileId=051205&sourceType=1 OAKBROOK TERRACE, IL --
Sign-up for Redbox Games Week Is Back August 10-16 investment picks
2014/9/2
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- You can call it "stupid news," and Twitter's bean counters must absolutely love this phenomenon.
Sign-up for Twitter, let's leave behind summer frivolity investment picks
2014/6/18
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- Amazon.com Inc. CEO Jeff Bezos is the world's greatest media manipulator.
Sign-up for UPDATE: Amazon's media-savvy Bezos is the new Steve Jobs investment picks
2014/7/15
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- The strict dictionary definition of a "carney" (or a "carny") denotes someone who works in a carnival.
Sign-up for Why the aptly named Carney would flop at Apple investment picks
2014/7/15
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- Buoyed by its World Cup success, Univision's profile is increasing in the United States on Main Street --
Sign-up for UPDATE: Univision becomes takeover bait amid World Cup investment picks
2014/7/14
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- Buoyed by its World Cup success, Univision's profile is increasing in the United States on Main Street --
Sign-up for Univision becomes takeover bait amid World Cup investment picks
2014/7/4
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- ABC wants its new evening-news anchor, David Muir, to be nothing less than a game-changer in the 6:30 p.m. sweepstakes.
Sign-up for UPDATE: Sawyer hands off No. 1 spot to 'Brad Pitt of TV news' investment picks
2014/7/3
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- ABC wants its new evening-news anchor, David Muir, to be nothing less than a game-changer in the 6:30 p.m. sweepstakes.
Sign-up for UPDATE: Sawyer hands off No. 1 spot to 'Brad Pitt of TV news' investment picks
2014/7/24
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- Right now, Facebook is flying so high that the worst thing you can say about the social media giant is that someday it may be remembered as an "Icarus stock." It has soared so close to the sun that it may eventually have to start to plummet, simply from getting up so high.
Sign-up for Is Facebook doomed to fly too high? investment picks
2014/8/1
By Jon Friedman, MarketWatch Opinion: One good quarter doesn't change anything -Jon Friedman; 415-439-6400; AskNewswires@dowjones.com NEW YORK (MarketWatch) -- Ah, Wall Street.
Sign-up for UPDATE: Is Twitter-mania misguided? investment picks
2014/7/30
By Jon Friedman, MarketWatch NEW YORK (MarketWatch) -- In the affluent land of Facebook Nation, nobody has to ask scornfully: Where are the shareholders' hoodies?
Sign-up for UPDATE: Zuckerberg on his way to becoming the richest person investment picks
By Jon Friedman, MarketWatch Opinion: Time for cable-news channel to earn some respect -Jon Friedman; 415-439-6400; AskNewswires@dowjones.com NEW YORK (MarketWatch) -- It's time for CNN to put up or shut up.
Sign-up for CNN: Put up or (please) shut up investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials to CNN: Put up or (please) shut up
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices